Research Output Journal of Public Health and Medicine 4(1):1-7, 2024

ROJPHM

ISSN ONLINE: 1115-9715
ISSN PRINT: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

https://doi.org/10.59298/ROJPHM/2024/411700

The Significance of Artificial Intelligence and Machine Learning in the Identification of Immunotherapy Targets for Cancer: Advances, Challenges, and Future Directions

Kungu Erisa

Department of Pharmacognosy Kampala International University Uganda
Email: erisa.kungu@studwc.kiu.ac.ug

ABSTRACT

Cancer immunotherapy has revolutionized cancer treatment by leveraging the immune system to target malignant cells, yet resistance in many cancers highlights the need for novel therapeutic targets. Artificial intelligence (AI) and machine learning (ML) have emerged as transformative tools for identifying new immunotherapy targets by analyzing vast datasets from genomics, proteomics, and clinical studies. This review explores the role of AI and ML in advancing the discovery of cancer-specific immunotherapy targets, such as tumor antigens and immune pathways. Key advances include the integration of big data, neoantigen prediction, biomarker discovery, and single-cell analysis. Despite these advancements, challenges remain, including data quality and standardization, interpretability of AI models, computational costs, and the need for biological validation of AI-driven discoveries. As AI and ML technologies continue to evolve, they hold the potential to overcome these barriers, leading to personalized immunotherapy solutions. This review also discusses future directions for AI-driven immunotherapy, emphasizing the need for improved models, ethical considerations, and clinical integration.

Keywords: Artificial Intelligence, Machine Learning, Immunotherapy, Cancer, Advances, Challenges, Future Directions

INTRODUCTION

Cancer immunotherapy has transformed the landscape of cancer treatment by engaging the immune system to attack malignant cells. Immunotherapies like immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) and CAR T-cell therapies have yielded remarkable success, particularly in cancers such as melanoma and certain types of leukemia [1] [2]. However, many cancers remain resistant to these treatments, underscoring the need for the discovery of new therapeutic targets. Artificial intelligence (AI) and machine learning (ML) have emerged as critical tools in cancer research, offering new possibilities for analyzing vast datasets from genomics, proteomics, and clinical studies. The ability of AI and ML to process and analyze large amounts of complex data makes them powerful for identifying novel immunotherapy targets, including tumor antigens and immune pathways [3]. This review explores the significance of AI and ML in advancing the identification of cancer-specific immunotherapy targets, highlights recent advances, addresses challenges, and considers future directions.

Advances in AI and ML for Immunotherapy Target Identification

AI and ML technologies are being increasingly utilized to streamline and enhance cancer immunotherapy target discovery [4]. Advances in these technologies have led to breakthroughs in several areas:

Big Data Integration and Analysis

AI and ML systems are equipped to process large volumes of multi-omics data—genomic, transcriptomic, proteomic, and epigenetic—allowing researchers to uncover hidden patterns and correlations that are critical for identifying novel targets. High-throughput sequencing technologies, such as next-generation sequencing (NGS), have generated a massive influx of data [5]. AI-based platforms can integrate and analyze these datasets efficiently to identify tumor-specific mutations, neoantigens, and immune evasion mechanisms that could serve as immunotherapy targets.

Neoantigen Prediction

One of the key breakthroughs in cancer immunotherapy has been the identification of neoantigens—new antigens that arise from cancer-specific mutations and can be recognized by the immune system. ML models, such as neural networks and support vector machines (SVMs), have shown great potential in predicting neoantigens from tumor sequences [6]. These algorithms analyze sequence data to predict which mutations are likely to produce immunogenic neoantigens, offering personalized immunotherapy solutions for individual patients [7].

Biomarker Discovery

AI and ML techniques have been instrumental in the discovery of biomarkers that predict patient response to immunotherapies. For instance, machine learning algorithms can analyze clinical data along with molecular profiles to identify biomarkers associated with positive responses to checkpoint inhibitors or CAR T-cell therapies [8]. These models help in patient stratification and personalized medicine, ensuring that the right patients receive the most effective therapies.

Single-Cell Analysis

With the advent of single-cell RNA sequencing (scRNA-seq), AI and ML are being employed to identify immunotherapy targets at the single-cell level [9]. Single-cell analysis allows for the characterization of tumor microenvironments and immune cell populations within tumors. AI algorithms can analyze this data to identify immune cell types, their interactions with cancer cells, and potential immune escape mechanisms, providing a more refined understanding of targetable pathways [10].

Challenges in AI and ML for Cancer Immunotherapy Target Discovery

Despite the promise AI and ML hold for advancing cancer immunotherapy, several challenges must be addressed:

Data Quality and Standardization

The effectiveness of AI and ML algorithms relies heavily on the quality and consistency of input data. Cancer datasets are often heterogeneous, with varying degrees of quality due to differences in sample collection, sequencing methods, and clinical data annotation [11]. Standardizing data collection and processing protocols is critical to ensure reliable and reproducible results.

Interpretability of AI Models

AI models, especially deep learning systems, are often criticized for being "black boxes," meaning that their decision-making processes are not easily interpretable by humans. This lack of transparency can be problematic in clinical settings, where understanding the reasoning behind a model's predictions is essential [12]. Efforts are being made to improve model interpretability through explainable AI (XAI) techniques, but this remains an ongoing challenge.

Computational Costs

AI and ML algorithms, particularly deep learning models, require significant computational resources, including powerful GPUs and access to large, high-quality datasets. For many research institutions, the costs associated with maintaining such infrastructure can be prohibitive, slowing the pace of discovery [13].

Validation of AI-Driven Discoveries

Even when AI models identify promising new immunotherapy targets, these findings must undergo extensive biological validation [14]. The process of translating AI-driven discoveries from computational models to clinical therapies is long and involves rigorous laboratory testing, animal models, and clinical trials, which can take years or even decades.

Mechanisms of Cancer Immunotherapy

Cancer immunotherapy is designed to harness and enhance the body's immune system to target and destroy cancer cells [15]. Unlike traditional therapies such as chemotherapy and radiation, which attack cancer directly, immunotherapy leverages the body's natural defenses to fight cancer. Key mechanisms of immunotherapy include the following:

Immune Checkpoint Inhibitors (ICIs): One of the most significant advancements in cancer immunotherapy is the development of immune checkpoint inhibitors. These drugs target inhibitory receptors or ligands on immune cells and cancer cells that normally act as brakes on the immune system, preventing it from attacking tumors [16]. Cancer cells exploit these immune checkpoints to evade detection and destruction by immune cells. The two most studied checkpoints are:

- **PD-1/PD-L1 Pathway**: The programmed death-1 (PD-1) receptor is found on T cells, and its ligand PD-L1 is expressed on tumor cells. When PD-1 binds to PD-L1, T cell activity is suppressed, allowing cancer cells to escape immune attack [17]. Drugs like pembrolizumab and nivolumab block this interaction, reactivating T cells to attack the tumor.
- **CTLA-4 Pathway**: CTLA-4 is another immune checkpoint found on T cells. Like PD-1, it downregulates immune activity. Ipilimumab, an anti-CTLA-4 drug, prevents the inhibition of T cells, enhancing their ability to kill cancer cells.

CAR T-cell Therapy: Chimeric antigen receptor (CAR) T-cell therapy is a personalized form of immunotherapy in which a patient's own T cells are genetically engineered to express receptors that recognize specific proteins on cancer cells. These modified T cells are then reinfused into the patient, where they actively seek and destroy cancer cells. CAR T-cell therapy has shown remarkable success in treating certain blood cancers, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma [18]. However, challenges remain in adapting this therapy for solid tumors due to the tumor microenvironment and difficulty in finding suitable antigens that are only expressed on cancer cells [19].

Cancer Vaccines: Cancer vaccines aim to stimulate the immune system to recognize and attack cancer-specific antigens, just as vaccines for infectious diseases prepare the body to fight off pathogens. These vaccines can be made from tumor cells, tumor antigens, or other immune-stimulating molecules that enhance the immune system's ability to detect and destroy cancer cells [20]. Although cancer vaccines have not yet achieved the same success as other immunotherapies, ongoing research seeks to improve their efficacy in treating various cancers.

Adoptive Cell Transfer (ACT): Adoptive cell transfer involves isolating immune cells from a patient, expanding or modifying them in the lab to enhance their cancer-fighting capabilities, and then reinfusing them into the patient [21]. This technique can involve tumor-infiltrating lymphocytes (TILs), which are extracted from the tumor itself and expanded, or genetically engineered T cells (like CAR T-cells). ACT aims to boost the patient's immune response to cancer, particularly in cases where the immune system is unable to mount a strong enough response on its own.

The Need for New Targets

While immunotherapy has transformed cancer treatment, it has also revealed limitations, especially in certain cancers that remain resistant to these therapies [22]. This resistance is often due to the complex interactions between the immune system and tumors, as well as the ability of tumors to evade immune detection. Some of the key challenges include:

Tumor Heterogeneity: Tumor heterogeneity refers to the genetic and phenotypic differences within and between cancer cells in the same tumor. This variability can make it difficult for immunotherapies to target all cancer cells effectively [23]. Some cells may express the target antigen, while others do not, allowing certain cancer cells to escape immune-mediated destruction. As a result, tumors can adapt and become resistant to treatment over time.

Immune Evasion: Cancer cells have evolved various mechanisms to evade immune detection. For example, they can downregulate antigen presentation, secrete immunosuppressive factors, or recruit regulatory immune cells that inhibit the anti-tumor immune response [24]. This immune evasion contributes to the failure of current immunotherapies in some cancers, necessitating the discovery of new targets that can overcome these escape mechanisms.

Lack of Universal Biomarkers: Many immunotherapies are designed to target specific proteins or pathways that may not be present in all patients or all types of cancer. For example, PD-L1 expression is used as a biomarker to predict response to PD-1/PD-L1 inhibitors, but not all patients with cancer express PD-L1, and some who do may still not respond to the therapy [25]. The identification of more universal and reliable biomarkers is essential to improve the effectiveness of immunotherapy and expand its applicability across different cancers.

Tumor Microenvironment (TME): The tumor microenvironment, which consists of immune cells, blood vessels, and extracellular matrix components surrounding the tumor, plays a crucial role in tumor progression and response to therapy [26]. The TME can either promote or inhibit immune responses. For example, some tumors create an immunosuppressive microenvironment by attracting regulatory T cells (Tregs) or myeloid-derived

suppressor cells (MDSCs) that inhibit the activity of cytotoxic T cells. Overcoming the immunosuppressive barriers of the TME is an important area of research for developing more effective immunotherapies.

Emerging Resistance: Even in cancers where immunotherapy has shown success, resistance often develops over time. Tumors may adapt by mutating or downregulating the expression of the targeted antigen, altering immune checkpoints, or modifying the tumor microenvironment to evade continued immune surveillance [4]. This resistance underscores the need for new targets and combination therapies to sustain the efficacy of immunotherapies and prevent relapse.

Role of Artificial Intelligence and Machine Learning in Cancer Research

Artificial Intelligence (AI) and machine learning (ML) are two powerful technologies that can be used in cancer research. AI simulates human intelligence in machines, while ML uses algorithms to learn from data and identify patterns. These technologies are particularly useful in processing large and complex datasets. They can be applied to genomic and transcriptomic analysis, proteomics and biomarker discovery, tumor microenvironment analysis, and drug discovery and optimization [16]. These techniques help identify mutations, expression patterns, and signatures related to cancer progression, identify potential therapeutic targets, and optimize drug design.

AI and ML in Identifying Immunotherapy Targets

Genomic data mining and machine learning (ML) algorithms can be used to identify potential immunotherapy targets in cancer. These include predicting neoantigens, which are novel antigens arising from cancer-specific mutations, and identifying driver mutations, which are crucial for tumor growth and may serve as therapeutic targets. The tumor microenvironment (TME) plays a pivotal role in modulating the immune response to cancer. AI and ML can analyze the heterogeneity of the TME, identifying immune cells and signaling pathways that contribute to immune evasion. Applications include immune cell profiling, single-cell RNA sequencing, and predicting immune checkpoint molecules that contribute to immune suppression in the TME. Predictive biomarkers for immunotherapy response are crucial for patient stratification and treatment personalization [20]. AI models can assess tumor mutational burden (TMB) and calculate immune infiltration scores based on RNA expression data. Key AI/ML technologies in cancer immunotherapy target discovery include Deep Learning (DL), Natural Language Processing (NLP), and Reinforcement Learning (RL). DL uses artificial neural networks to model complex biological processes, while NLP extracts valuable insights from unstructured clinical and research data. RL can optimize treatment strategies by simulating different therapeutic interventions and learning from outcomes, enabling the optimization of dosing regimens and identification of synergistic drug combinations, including immunotherapies.

Challenges in AI/ML-Driven Immunotherapy Target Discovery

Data Quality and Standardization

AI and ML models rely on high-quality, well-annotated datasets. However, cancer research often suffers from fragmented, heterogeneous, and noisy data, which can hinder model accuracy and generalization. Standardizing data collection, processing, and integration is crucial for effective AI applications.

Interpretability and Validation

One of the limitations of AI/ML models, especially deep learning, is their "black box" nature. The lack of interpretability makes it challenging to validate the biological relevance of predicted targets. Efforts to improve model transparency and biological validation are needed.

Ethical and Regulatory Considerations

The use of AI in healthcare raises ethical concerns regarding patient privacy, data security, and algorithmic bias. Regulatory frameworks must evolve to ensure that AI-driven discoveries are safe, equitable, and applicable across diverse populations.

Future Directions and Innovations

Looking ahead, AI and ML will continue to revolutionize the field of cancer immunotherapy by enhancing the speed, accuracy, and scale of target discovery. Some promising future directions include:

AI-Driven Drug Development

AI and ML models are being developed to predict not only immunotherapy targets but also the efficacy of drugs designed to interact with those targets. These models can simulate drug-tumor interactions, allowing researchers to design more effective therapies with fewer side effects. This approach, known as in silico drug development, has the potential to drastically reduce the time and cost required to bring new therapies to market.

Multi-Omics Integration

As multi-omics datasets become more comprehensive, AI models will be further refined to integrate data from multiple biological layers, including genomics, epigenomics, proteomics, and metabolomics. This holistic approach will provide a more complete picture of the tumor-immune system interaction, leading to the identification of novel therapeutic targets that were previously missed.

Personalized Immunotherapy

AI and ML hold the key to truly personalized immunotherapy. By integrating data from a patient's genomic, transcriptomic, and clinical profiles, AI systems can predict the most effective immunotherapy strategies for individual patients. This personalized approach will not only improve treatment outcomes but also reduce the likelihood of adverse effects.

Collaborative AI Networks

The future of AI in cancer immunotherapy will likely involve collaborative networks, where researchers from different institutions and disciplines share data and algorithms. These networks will enable more robust AI models that can be trained on diverse datasets, improving their generalizability and applicability to a wider range of cancers.

CONCLUSION

In conclusion, the integration of artificial intelligence (AI) and machine learning (ML) in the identification of immunotherapy targets for cancer holds immense potential for advancing personalized treatment strategies. These technologies have significantly enhanced our ability to analyze complex, multi-omics data, predict neoantigens, discover biomarkers, and profile immune cells within the tumor microenvironment. While AI and ML have driven remarkable progress, challenges such as data quality, model interpretability, computational costs, and the need for biological validation must be addressed to fully realize their potential in cancer research.

Looking ahead, improvements in explainable AI (XAI) could provide greater transparency in model decision-making, enabling clinicians to better trust and apply AI-driven discoveries. Furthermore, the development of standardized data-sharing frameworks and collaborative platforms will ensure high-quality, diverse datasets, facilitating more robust AI models. Future innovations may also involve the integration of AI with emerging technologies like quantum computing to further enhance the identification of immunotherapy targets and optimize treatment strategies. Ultimately, the continued evolution of AI and ML in cancer immunotherapy research promises to not only overcome current limitations but also to unlock novel, more effective therapeutic targets, offering hope for improved cancer outcomes across a broader range of patients.

REFERENCES

1. Berrondo, C., Saleh, R., & Al-Olayan, A. (2022). Challenges in AI-based immunotherapy target discovery: From data quality to biological validation. Trends in Cancer, 8(11), 922-933. https://doi.org/10.1016/j.trecan.2022.07.009
2. Obeagu, E. I., Alum, E. U., Obeagu, G.U. and Ugwu, O. P. C. Benign Prostatic Hyperplasia: A Review. Eurasian Experiment Journal of Public Health (EEJPH). 2023; 4(1): 1-3.https://www.eejournals.org/public/uploads/1687980288_52785ca83cc0c789d8ae.pdf
3. Ibiam, U. A., Uti, D. E., Ejeogo, C. C., Orji, O. U., Aja, P. M., Ezeaani, N. N., Alum, E. U.,Chukwu, C., AlokeC., Chinedum, K. E., Agu, P. and Nwobodo, V.In Vivo and in Silico Assessment of Ameliorative Effects of Xylopiaaethiopica on Testosterone Propionate-Induced Benign Prostatic Hyperplasia.Pharmaceut Fronts. 2023;5: e64–e76.DOI:10.1055/s-0043-1768477
4. Alum, E. U., Inya, J. E., Ugwu, O. P. C., Obeagu, I. E., Aloke, C., Aja, P. M., Okpata, M. G., John, E. C., Orji, M. O. and Onyema, O. Ethanolic leaf extract of Daturastramonium attenuates Methotrexate-induced Biochemical Alterations in Wistar Albino rats. RPS Pharmacy and Pharmacology Reports, 2023; 2(1):1–6. doi: 10.1093/rpsppr/rqac011.
5. Aja, P. M., Agu, P. C., Ezeh, E. M., Awoke, J. N., Ogwoni, H. A., Deusdedit, T., Ekpono, E. U., Igwenyi, I. O., Alum, E. U.,Ugwuja, E. I., Ibiam, U. A., Afiukwa, C. A. and Adegboyega, A. E. Prospect into therapeutic potentials of Moringa oleifera phytocompounds against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies. Bulletin of the National Research Centre. 2021; 45(1): 1-18. https://doi.org/10.1186/s42269-021-00554-6.
6. Obeagu, E. I., Ahmed, Y. A., Obeagu, G. U., Bunu, U. O., Ugwu, O. P. C. and Alum, E. U. Biomarkers of breast cancer: Overview. Int. J. Curr. Res. Biol. Med., 2023; (1): 8-16. DOI:10.22192/ijcrbm.2023.08.01.002.

7. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I.,Ugwu, C. N.Beyond Conventional Therapies: Exploring Nutritional Interventions for Cervical Cancer Patients, J, Cancer Research and Cellular Therapeutics, 8(1);1-6. DOI:10.31579/2640-1053/180
8. Davis, M. M., Benitez, A., & Liu, J. (2023). Explainable AI in immunotherapy: A roadmap to model interpretability and clinical integration. Nature Machine Intelligence, 5(8), 634-645. https://doi.org/10.1038/s42256-023-00678-5
9. Kapoor, A., Singh, P., & Chatterjee, S. (2023). Computational challenges in AI-driven cancer immunotherapy target discovery. Journal of Computational Biology, 30(7), 587-599. https://doi.org/10.1089/cmb.2023.0021
10. Ibiam U. A., Uti, D. E., Ejeogo, C.C., Orji, O. U. Aja, P. M., Ezeani, N. N., Alum, E. U., Chukwu, C., Aloke, C., Itodo, M. O., Agada, S. A., Umoru, G. U., Obeten, U. N., Nwobodo, V. O. G., Nwadum, S. K., Udoudoh, M. P. Xylopiaaethiopica Attenuates Oxidative Stress and Hepatorenal Damage in Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. Journal of Health and Allied Sciences. 2024, 01: 1-148. https://doi.org/10.1055/s-0043-1777836.
11. Alum, E, U., Uti D, E., Obeagu E, I., Ugwu, O, P, C., Alum, B, N. Cancer's Psychosocial Aspects: Impact on Patient Outcomes. Elite Journal of Medicine, 2024; 2(6): 32-42.
12. Ugwu O, P, C, Anyanwu C, N, Alum E, U, Okon M, B, Egba S, I, Uti D, E and Awafung E, A. (2024).CRISPR-Cas9 Mediated Gene Editing for Targeted Cancer Therapy: Mechanisms, Challenges, and Clinical Applications. Newport International Journal of Biological And AppliedSciences,5(1):97-102. https://doi.org/10.59298/NIJBAS/2024/5.1.9297102
13. Alum E, U., Uti D, E., Obeagu E, I., Ugwu O, P, C., Alum B, N.. Cancer's Psychosocial Aspects: Impact on Patient Outcomes. Elite Journal of Medicine, 2024; 2(6): 32-42.
14. Obeagu, E. I., Omar, D. E., Bunu, U. O., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Leukaemia burden in Africa. Int. J. Curr. Res. Biol. Med., 2023; (1): 17- 22. DOI:10.22192/ijcrbm.2023.08.01.003
15. Obeagu, E. I., Alum, E. U., Obeagu, G.U. and Ugwu, O. P. C. Prostate Cancer: Review on Risk Factors. Eurasian Experiment Journal of Public Health (EEJPH). 2023; 4(1): 4-7.https://www.eejournals.org/public/uploads/1688032824_872978821ba373725554.pdf
16. Huang, X., Zhang, L., & Dong, L. (2023). AI-driven discovery of cancer immunotherapy targets: Integrating multi-omics data for precision medicine. Nature Reviews Drug Discovery, 22(2), 134-148. https://doi.org/10.1038/s41573-022-00234-7
17. Mittal, S., Venugopal, C., & Wen, Y. (2023). Machine learning models for neoantigen prediction in cancer immunotherapy. Frontiers in Immunology, 14, 10476. https://doi.org/10.3389/fimmu.2023.00123
18. Alum, E. U., Famurewa, A. C., Orji, O. U., Aja, P. M., Nwite, F., Ohuche, S. E., Ukasoanya, S. C., Nnaji, L. O., Joshua, D., Igwe, K. U. and Chima, S. F. Nephroprotective effects of Daturastramonium leaves against methotrexate nephrotoxicity via attenuation of oxidative stress-mediated inflammation and apoptosis in rats. Avicenna Journal of Phytomedicine. 2023; 13(4): 377-387. doi: 10.22038/ ajp.2023.21903.
19. Tseng, Y. Y., Wang, L., & Lee, W. J. (2023). Leveraging AI and single-cell RNA-sequencing to identify immune evasion mechanisms in tumors. Journal of Cancer Research and Immunotherapy, 189(3), 456-470. https://doi.org/10.1007/s00262-023-03456-x
20. Alum, E. U., Obeagu, E. I., Ugwu, O. P. C., Orji, O. U., Adepoju, A. O., Amusa, M. O. Edwin, N.Exploring natural plant products in breast cancer management: A comprehensive review and future prospects.International Journal of Innovative and Applied Research. 2023; 11(12):1-9.Article DOI:10.58538/IJIAR/2055. DOI URL:http://dx.doi.org/10.58538/IJIAR/2055
21. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Cervical Cancer Prevention Paradox: Unveiling Screening Barriers and Solutions, J, Cancer Research and Cellular Therapeutics. 2024, 8(2):1-5. DOI:10.31579/2640-1053/182
22. Alum, E, U, Obeagu E, I, Ugwu O, P, C. Cervical Cancer Unveiled: Insights into HPV, Risks, and Therapeutic Frontiers. Elite Journal of Public Health, 2024; 2 (6): 55-66.
23. Nunes, A. T., Liang, S., & Zhang, Q. (2023). Artificial intelligence for biomarker discovery in cancer immunotherapy: Current landscape and future directions. Cancer Research, 83(6), 1112-1122. https://doi.org/10.1158/0008-5472.CAN-23-0345

24. Zhao, Y., Yang, P., & Shen, J. (2023). Multi-omics data integration using machine learning for cancer immunotherapy target identification. Bioinformatics, 39(5), btab472. https://doi.org/10.1093/bioinformatics/btab472
25. Qin, S., Zhang, H., & Li, M. (2023). Deep learning approaches for immunotherapy response prediction in cancer patients. Nature Biotechnology, 41(4), 567-579. https://doi.org/10.1038/s41587-023-00852-4
26. O'Connor, M. J., Tiwari, P., & Wu, Z. (2022). AI and machine learning applications in identifying tumor antigens for personalized cancer vaccines. Nature Communications, 13(1), 4598. https://doi.org/10.1038/s41467-022-32208-5

CITE AS: Kungu Erisa (2024). The Significance of Artificial Intelligence and Machine Learning in the Identification of Immunotherapy Targets for Cancer: Advances, Challenges, and Future Directions. Research Output Journal of Public Health and Medicine 4(1):1-7. https://doi.org/10.59298/ROJPHM/2024/411700